文献速递肿瘤 PET/CT核素与放射性配体治疗

不良中危及高危前列腺癌根治性放疗前前列腺特异性膜抗原PET/CT的随机试验(PSMA-dRT试验)

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
PubMed 文献 · J Nucl Med · 2024-07-01

这项多中心随机III期试验(NCT04457245)评估根治性放疗前进行前列腺特异性膜抗原(PSMA)PET/CT的效果,将不良中危或高危前列腺癌男性按1.08:1随机分为接受与不接受PSMA PET/CT扫描两组,主要终点为5年无进展生存期。2020年11月至2021年12月共随机54人(PSMA PET/CT组n=25,对照组n=29),试验在PSMA PET/CT获批及保险覆盖后提前关闭。PSMA PET/CT组中4例患者分期上调,结论称PSMA PET/CT使17%患者分期上调,从而允许更准确的放疗计划,但试验提前关闭且把握度不足。

要点

  • PSMA PET/CT使17%患者分期上调,允许更准确放疗计划。
  • 试验提前关闭,仅随机54/316(17%),把握度不足评估无进展生存影响。
  • PSMA PET/CT组25例中4例分期上调,包括局部晚期、区域转移和远处转移。

核心结论

  • PSMA PET/CT使17%患者分期上调,从而允许更准确的放疗计划。
  • 试验在完成目标入组前提前关闭(54/316,17%),把握度不足评估PSMA PET/CT对无进展生存期的影响。

研究设计与样本

  • 多中心随机III期试验(NCT04457245),不良中危或高危前列腺癌男性按1.08:1随机接受或不接受根治性放疗前PSMA PET/CT扫描。
  • 对照组允许所有其他影像学检查方式,主要终点为5年无进展生存期。
  • 2020年11月至2021年12月共随机54人:PSMA PET/CT组n=25,对照组n=29。

主要发现

  • PSMA PET/CT组25例中,14例为局限性疾病(miT2b-cN0M0),6例为局部晚期疾病(miT3a-bN0M0),3例为区域转移(miN1M0),1例为远处转移(miM1b)。
  • PSMA PET/CT组4例患者分期上调。
  • 试验在PSMA PET/CT获批及保险覆盖后提前关闭。

关键数值与推荐

  • PSMA PET/CT使17%患者分期上调。
  • 试验提前关闭,随机54/316(17%),把握度不足评估PSMA PET/CT对无进展生存期的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验在完成目标入组前提前关闭(54/316,17%),把握度不足评估PSMA PET/CT对无进展生存期的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy. Methods: Men with unfavorable intermediate- or high-risk prostate cancer were randomized 1.08:1 between receiving and not receiving a PSMA PET/CT scan before definitive radiotherapy. All other imaging modalities were allowed in the control arm. The primary endpoint was 5-y progression-free survival. Results: Fifty-four men were randomized between November 2020 and December 2021 (PSMA PET/CT, n = 25; control, n = 29). The trial closed early after approval and insurance coverage of PSMA PET/CT. In the PSMA PET/CT arm, 14 patients had localized disease (miT2b-cN0M0), 6 had locally advanced disease (miT3a-bN0M0), 3 had regional metastasis (miN1M0), and 1 had distant metastasis (miM1b). Four patients were upstaged. Conclusion: PSMA PET/CT upstaged 17% of patients, which allowed for more accurate radiotherapy planning. Unfortunately, this trial closed early before completion of target enrollment (54/316, 17%) and was underpowered to assess the effect of PSMA PET/CT on progression-free survival.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nikitas J, Lam E, Booker KA, et al. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). J Nucl Med. 2024. PMID: 38664019. doi:10.2967/jnumed.123.267004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。